Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099461 · ClinicalTrials.gov registry record · Phase 1
Effect of Denosumab on Cellular Biomarkers in the Human Breast
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT02099461 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 82 participants.
The verdict
NCT02099461, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
To evaluate whether administration of denosumab results in a decrease compared to the control group in proliferation of mammary epithelial cells as measured by the Ki-67 proliferation index.
Interventions
- DRUG Denosumab
- PROCEDURE Percutaneous core needle breast biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02099461
The ClinicalTrials.gov registry entry for NCT02099461 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Denosumab is the first listed.
NCT02099461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02099461 about?
NCT02099461 is a clinical study titled "Effect of Denosumab on Cellular Biomarkers in the Human Breast". To evaluate whether administration of denosumab results in a decrease compared to the control group in proliferation of mammary epithelial cells as measured by the Ki-67 proliferation index.
What is the current status of trial NCT02099461?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2014-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT02099461?
The interventions under investigation include: Denosumab (DRUG), Percutaneous core needle breast biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02099461?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.